#ACTRIMS2021 – Expert Lectures About Available NMOSD Treatments

An improved understanding of the biological processes that drive neuromyelitis optica spectrum disorder (NMOSD) has led to treatment advancements in recent years. In a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, Sean Pittock, MD, director of the Mayo Clinic’s Center for…

Dysphagia May Be Sign of Brain Damage in NMOSD and MOGAD Patients

People with neuromyelitis optica spectrum disorder (NMOSD) with difficulty swallowing are more likely to have clinical signs of brain involvement and more extensive disability, a small study suggests. Measures of a patient’s difficulty with swallowing could be used to indirectly assess brain involvement in NMOSD and the related disorder…